

how quality improvement science has great applicability in infection prevention and hospital epidemiology. These measures aim to significantly reduce SSI rates and improve patient care.

Antimicrobial Stewardship & Healthcare Epidemiology 2025;5(Suppl. S2):s149–s150  
doi:10.1017/ash.2025.412

**Presentation Type:**  
Poster Presentation  
**Subject Category:** SSI

**A Deep Dive into Post-Cesarean Section Surgical Site Infections**  
Rija Alvi<sup>1</sup>, Clare Shanahan<sup>2</sup>, Abigail Ruby<sup>3</sup>, Eman Chami<sup>3</sup> and Geehan Suleyman<sup>4</sup>  
<sup>1</sup>Henry Ford Hospital; <sup>2</sup>Henry Ford Health System; <sup>3</sup>Henry Ford Health System and <sup>4</sup>Henry Ford Health

Surgical site infection (SSI) is one of the most common complications following cesarean section (CSEC) and adds significant burden to the healthcare system. We aimed to explore factors associated with increased risk of these infections and to compare disease severity based on tissue level. Observational study of post-CSEC SSIs from Jan 2021-Dec 2023 at Henry Ford Hospital in Detroit. SSIs were defined according to National Healthcare Safety Network (NHSN) criteria. Cases were categorized as superficial incisional (SI), deep incisional (DI) and organ space (OS). Demographics, risk factors, clinical features and outcomes were evaluated. DI and OS were grouped together into non-superficial infections for comparative analysis. 70 (3%) of 2,230 CSECs performed during the study period met post-CSEC SSI criteria, of which 41 (60%) were SI, 4 (6%) DI, and 25 (34%) OS (Table 1). Majority of patients were black (51.5%) with BMI>30 (56%), had Medicaid insurance (66%) and underwent emergent CSEC (60%). Anemia (hemoglobin 3 manual exams prior to surgery (55% vs. 29%, p=0.017) were significantly more common among patients with non-superficial infections. Receipt of perioperative antibiotics was similar between the two groups, and most were administered within 1 hour of incision; cefazolin was frequently used. Incisional pain and drainage were the most prevalent symptoms (Table 2). Abdominal pain (69% vs. 10%, 3 manual exams and worse clinical outcomes compared to patients

Table 1: Demographics, comorbidities, and risk factors associated with post-CSEC SSI

	Total, N=70 (%)	Superficial Infection, N=41 (%)	Non-superficial infection, N = 29 (%)	P-value
<b>Demographics</b>				
Mean age (SD), years	30.3 (5.2)	31.5 (5.2)	28.6 (4.9)	0.689
BMI > 30	39 (55.7)	25 (60.9)	14 (48.2)	0.292
Black Race	36 (51.5)	15 (36.6)	21 (72.4)	0.003
Medicaid insurance	46 (65.7)	28 (68.3)	18 (62.1)	0.589
<b>Comorbidities and Risk factors</b>				
Anemia	28 (40)	14 (34.1)	14 (48.2)	0.457
Diabetes	13 (14.3)	12 (29.3)	1 (3.4)	0.006
Chorioamnionitis	9 (12.9)	2 (4.8)	7 (24.1)	0.018
Smoker	3 (4.3)	0 (0)	3 (10.3)	0.035
Asthma	10 (14.3)	4 (9.7)	6 (20.7)	0.198
Hypertension	25 (35.7)	12 (29.2)	13 (44.8)	0.181
Group B streptococcus	19 (27.1)	14 (34.1)	5 (17.2)	0.292
Perinatal STI	5 (7.1)	2 (4.8)	3 (10.3)	0.382
Substance Use	14 (20)	9 (21.9)	5 (17.2)	0.627
Previous abdominal surgery	31 (44.3)	21 (51.2)	10 (34.5)	0.231
Previous CSEC	34	25 (60.9)	9 (31.0)	0.014
Hospitalized within 1 month	10 (14.3)	7 (17.1)	4 (13.8)	0.710
<b>C-section details</b>				
Rupture of Membranes	31 (44.2)	13 (31.7)	18 (62.1)	0.012
Vaginal prep candidate	28 (40)	12 (29.2)	16 (55.2)	0.029
Vaginal prep performed	13 (18.6)	5 (12.2)	8 (27.5)	0.103
Number of manual exams >3	19 (27.1)	12 (29.3)	16 (55.2)	0.017
Surgical skin prep	65 (92.8)	40 (97.5)	25 (86.2)	0.069
Emergency Surgery	42 (60)	19 (46.3)	23 (79.3)	0.006
EBL median (IQR), mL	885 (667-1383)	840 (561-1180)	1060 (698-1455)	0.322
Blood transfusion received	11 (15.7)	4 (9.7)	7 (24.1)	0.103
Peri-operative antibiotics	60 (85.7)	35 (85.3)	25 (86.2)	0.921
Abx administered <1 hour	48 (68.6)	28 (68.3)	21 (72.4)	0.711
<b>Post-op factors</b>				
Wound dressing removed	60 (85.7)	35 (85.4)	26 (89.7)	0.597
Wound clean/dry/intact	58 (82.9)	34 (82.9)	24 (82.8)	0.985
Post op anemia	69 (98.6)	41 (100)	28 (96.6)	0.231

EBL, estimated blood loss; STI, sexually transmitted infection

Table 2: Clinical manifestations and outcomes of patients with post-CSEC SSIs

	Total, N=70 (%)	Superficial Infection, N=41 (%)	Non-superficial infection, N = 29 (%)	P-value
<b>Symptoms</b>				
Time since Surgery at Onset of infection, mean (SD)	13 (7)	15 (7.1)	10.8 (6.5)	0.213
Incisional pain	38 (54.3)	24 (58.5)	14 (48.2)	0.396
Abdominal pain	24 (34.3)	4 (9.7)	20 (69.0)	<0.001
Fever	19 (27.1)	2 (4.9)	17 (58.6)	<0.001
Wound drainage	42 (60)	35 (85.4)	7 (24.1)	<0.001
Wound dehiscence	22 (31.4)	17 (41.5)	5 (17.2)	0.032
Vaginal discharge	7 (10)	1 (2.4)	6 (20.7)	0.012
Urinary symptoms	4 (5.7)	0 (0)	4 (13.8)	0.014
<b>Outcomes &amp; Complications</b>				
Received Antibiotics	60 (85.7)	34 (82.9)	26 (89.7)	0.428
Duration of antibiotics, median (IQR)	7 (7-10)	7 (7-10)	7 (7-10)	0.080
Multiple courses of antibiotics	6 (8.6)	1 (2.4)	5 (17.2)	0.026
Cultures obtained	24 (34.3)	13 (31.7)	11 (37.9)	0.589
Required readmission	24 (34.3)	5 (12.2)	19 (65.6)	<0.001
Multiple admissions	4 (5.7)	0 (0)	4 (13.8)	0.014
Length of Stay, median (IQR)	3 (2-6)	1 (1-2)	3 (2-5)	0.001
ICU stay	2 (2.9)	0 (0)	2 (6.9)	0.088
Needed intervention	18 (25.7)	5 (12.2)	13 (44.8)	0.004
IR drainage	7 (10)	3 (7.3)	4 (13.8)	
Surgical debridement	4 (5.7)	2 (4.9)	2 (6.9)	
Exploratory Laparotomy	7 (10)	0 (0)	7 (24.1)	
Uterine Dehiscence	6 (8.6)	0 (0)	6 (20.7)	0.002
Hysterectomy	3 (4.3)	0 (0)	3 (10.3)	0.035
Multiple interventions	1 (1.4)	0 (0)	1 (3.4)	0.231
Death	0 (0)	0 (0)	0 (0)	

with superficial infections. Implementing evidence-based practices and recommendations are therefore critical to reduce the morbidity associated with non-superficial CSEC infections.

Antimicrobial Stewardship & Healthcare Epidemiology 2025;5(Suppl. S2):s150  
doi:10.1017/ash.2025.413

**Presentation Type:**  
Poster Presentation  
**Subject Category:** Surveillance

**Survival Analysis of Carbapenem Resistant Enterobacterales (CRE) Cases in Davidson and Surrounding Counties, Tennessee, 2016-2022**  
Daniel Muleta<sup>1</sup>, Raquel Villegas<sup>2</sup>, Srilakshmi Velrajan<sup>3</sup>, Cherly Bailey<sup>4</sup>, Jackie Taylor<sup>5</sup>, Dr. Dipen M Patel<sup>5</sup>, Melphine Harriott<sup>6</sup> and Michael Norris<sup>7</sup>  
<sup>1</sup>Tennessee Department of Health; <sup>2</sup>state of TN; <sup>3</sup>TN Department of Health; <sup>4</sup>TN Dept of Health; <sup>5</sup>Tennessee Department of Health; <sup>6</sup>TN Department of Health HAI/AR Program and <sup>7</sup>State of Tennessee Department of Health

**Background:** Carbapenem-resistant Enterobacterales (CRE) have become an increasing public health challenge in the United States over the past two decades. Carbapenemase-producing CREs (CP-CREs) significantly contribute to the spread of antimicrobial-resistant pathogens in healthcare settings. Tennessee has been conducting surveillance of CRE since 2011. As

Table Multivariable Cox Regression Analysis of Factors Associated with 90-Day Mortality Rate				
Variables	Chi-Square	P < ChiSq	Hazard Ratio	Confidence interval
Age group (≤70 vs >70)	2.2176	0.1364	1.572	0.867-2.852
CP-CRE (Non-CP-CRE VS CP-CRE)	8.1610	0.0043	2.432	1.322 - 4.474
Sex (Male VS Female)	4.2408	0.0395	0.544	0.305 - 0.971
Charlson score (Low VS High)	18.6118	<.0001	4.176	2.182-7.996

CP-CRE: Carbapenemase producing CRE.  
Charlson score: High (≥5); Low (<5)